Last reviewed · How we verify
n-butyl chloride
n-Butyl chloride is a marketed small molecule with an unspecified primary indication, positioned in a segment where the exact mechanism of action remains unknown. The drug holds a key composition patent expiring in 2028, providing a period of exclusivity and potential market protection. The primary risk lies in the lack of detailed clinical trial results and revenue data, which may limit investor confidence and market adoption.
At a glance
| Generic name | n-butyl chloride |
|---|---|
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) (PHASE2,PHASE3)
- Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma (PHASE3)
- Hyoscine Butyl-bromide Versus Ondansetron for Nausea and Vomiting During Cesarean Section Under Spinal Anesthesia (PHASE4)
- Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma (PHASE1,PHASE2)
- Effect Of Intravenous Hyoscine -N-Butyl Bromide In Management Of Prolonged Labor In Nulliparous (NA)
- Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant (PHASE2)
- Safety Study of Hyoscine N Butyl Bromide in Active Management of Labor (PHASE4)
- Does the Hyoscine N-Butylbromide Administered During Colonoscopy Increase the Adenoma Detection Rate? (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- n-butyl chloride CI brief — competitive landscape report
- n-butyl chloride updates RSS · CI watch RSS
- portfolio CI